SCHEMBL4274142

SCHEMBL4274142

NCCCS(=O)(=O)N1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
SMN1; SMN2 Q16637 5/20 0.45
KEAP1 Q14145 1/20 0.45
ALDH1A1 P00352 3/20 0.45
APP P05067 1/20 0.41
TSHR P16473 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
SMYD3 Q9H7B4 3/20 0.38
KDM4E B2RXH2 1/20 0.37
GMNN O75496 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
THPO P40225 1/20 0.35
HBB P68871 1/20 0.35
PMP22 Q01453 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1389415 0.92 LMNA (0.46) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL1395247 0.92 LMNA (0.46) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL1395219 0.92 LMNA (0.46) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL455971 0.88 LMNA (0.51) LMNACA12CA7CA14SMN1; SMN2
Hydrochloric Acid SCHEMBL3665461 0.86 LMNA (0.50) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL15693585 0.83 CA12 (0.59) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL5618655 0.81 CA1 (0.42) LMNASMN1; SMN2ALDH1A1APPTSHR
SCHEMBL1667599 0.80 ALDH1A1 (0.49) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL7297373 0.80 ALDH1A1 (0.50) LMNACA12CA7CA14SMN1; SMN2
SCHEMBL1654776 0.80 LMNA (0.49) LMNACA12CA7CA14SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116199686-A Trifluoromethyl substituted sulfonamide compounds 正大天晴药业集团股份有限公司 2023-06-02 CN disclosed
EP-2285783-B1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-21 EP disclosed
US-8263597-B2 Indazole compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-11 US disclosed
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-01 US disclosed
WO-2009134666-A1 INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-05 WO disclosed
CN-1117291-A 4-Hydroxy-pyran-2-one derivatives for the treatment of retroviral infections UPJOHN CO (US) 1996-02-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294808-A1 Indazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCRL2 LMNA 4663/4885CA12 4158/4885CA7 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.